secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001104659-26-040171
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode secures up to $20M flexible financing from Yorkville via SEPA and convertible notes
--------------------------------------------------------------------------------

- Up to $14M SEPA for common stock sales at 97% of lowest 3-day VWAP; up to $6M in pre-paid convertible notes at 5% discount.
- First $1M convertible note tranche expected upon filing Form 10-K; second $5M tranche after registration and shareholder approval.
- Convertible notes bear 5% interest, mature 18 months, convertible at 115% of prior day VWAP or 95% of lowest 7-day VWAP, floor at 20% of last trade.
- Company issued 29.89 Series A Preferred shares as PIK dividend to DEFJ and Tungsten from prior acquisition on April 6, 2026.
- CEO states financing extends runway into late 2027/early 2028, enabling completion of Phase 2a trial for TTX-MC138.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926040171/0001104659-26-040171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926040171/tm2611272d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-040171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer